Biotechnology Research Integrity Law In Russia.
1. Introduction
Biotechnology Research Integrity Law in Russia concerns the legal and ethical standards governing honesty, scientific accuracy, transparency, accountability and responsible conduct in biotechnology research.
It applies to research involving:
Genetic engineering and genome editing.
Stem-cell research and regenerative medicine.
Human genetic testing and genomic databases.
Pharmaceutical and vaccine development.
Clinical trials and experimental therapies.
Synthetic biology and genetically modified organisms (GMOs).
Biotechnology research involving human biological samples.
Scientific publications, research data and laboratory experimentation.
Research integrity requires scientists, universities, laboratories, pharmaceutical companies and research institutions to conduct experiments honestly, report findings accurately and protect research participants.
An important legal distinction: Russia does not have one comprehensive federal statute exclusively dedicated to biotechnology research integrity. Instead, integrity obligations arise from several federal laws, clinical-trial regulations, professional standards, institutional ethics procedures and general civil, administrative and criminal law.
This distinction is important when examining Russian court decisions: a judgment concerning clinical-trial consent or medical negligence may establish a relevant integrity principle without being a direct ruling on scientific misconduct.
2. Constitutional and statutory foundations
A. Constitution of the Russian Federation
The Constitution provides the general foundation for lawful scientific activity.
Relevant provisions include:
Article 21: Protection of human dignity.
Article 23: Privacy and personal and family life.
Article 24: Protection of information concerning private life.
Article 41: Right to health protection and medical assistance.
Article 44: Freedom of scientific and other creative activity.
These provisions become relevant when biotechnology research involves human experimentation, genetic information, medical confidentiality or scientific freedom.
For example, a research institution cannot treat scientific objectives as an unrestricted justification for violating the dignity, privacy or health rights of research participants.
B. Federal Law No. 127-FZ of 23 August 1996
On Science and State Scientific and Technical Policy
This is one of the central laws governing scientific research in Russia.
It establishes the general legal framework for scientific and technological activities.
Article 4 recognises the rights and obligations of scientific workers.
Among the relevant obligations is the requirement that scientists conduct scientific, scientific-technical and experimental activities without violating human rights and freedoms, harming human life or health, or damaging the environment.
Its significance for biotechnology includes:
Responsible conduct of laboratory research.
Protection of human research participants.
Scientific objectivity in evaluating research projects.
Responsible performance of experiments.
Compliance with legal and environmental requirements.
A researcher who deliberately manipulates experimental results may also face consequences under employment rules, institutional procedures, research contracts or other applicable legislation.
Case-law significance: The law supplies the statutory foundation for assessing the legality of scientific conduct, although it does not establish a complete, specialised system for investigating every form of research misconduct.
rostransnadzor.gov.ru+1
C. Federal Law No. 61-FZ of 12 April 2010
On Circulation of Medicines
This law is particularly important for biotechnology companies developing:
Biological medicines.
Vaccines.
Recombinant proteins.
Gene-therapy products.
Cell-based medicinal products.
Biosimilars and other innovative pharmaceutical products.
Chapter 7 regulates clinical trials of medicinal products.
Important provisions include:
| Provision | Legal significance |
|---|---|
| Article 38 | Clinical trials and their purposes |
| Article 39 | Authorisation and organisation of clinical trials |
| Article 40 | Requirements relating to clinical-trial facilities and permissions |
| Article 41 | Clinical-trial contracts |
| Article 42 | Financing of clinical trials |
| Article 43 | Rights of clinical-trial participants |
Article 43 is especially important because it requires voluntary participation and written informed consent. Participants must receive information about the investigational medicine, risks, expected benefits, trial duration, insurance and confidentiality.
Participants can withdraw from a clinical trial at any stage.
These requirements promote research integrity by preventing researchers from concealing experimental risks or using participants without legally valid consent.
WIPO+1
D. Federal Law No. 323-FZ of 21 November 2011
On the Fundamentals of Health Protection of Citizens in the Russian Federation
This law establishes protections relevant to biomedical research.
Article 20 regulates informed voluntary consent to medical intervention and the right to refuse medical intervention.
Article 13 protects medical confidentiality.
Article 18 recognises the right to health protection.
Article 19 establishes the right to medical assistance.
In biotechnology research, these provisions are relevant where researchers obtain biological samples, conduct experimental medical interventions or collect sensitive clinical information.
For example, researchers cannot simply assume that consent to ordinary medical treatment automatically authorises participation in an unrelated genetic research project.
E. Federal Law No. 152-FZ of 27 July 2006
On Personal Data
This legislation is important because biotechnology research increasingly involves:
DNA profiles.
Genetic sequencing.
Health information.
Family genetic histories.
Biological identification data.
Clinical-trial participant databases.
Article 5 establishes principles governing personal-data processing, including purpose limitation and the requirement that processing be proportionate to its purposes.
Article 6 regulates the legal grounds for processing personal data.
Article 10 addresses special categories of personal data, including information concerning health and certain other sensitive characteristics.
Article 18.1 establishes obligations concerning the organisation of personal-data processing.
Consequently, researchers must establish appropriate legal grounds for collecting and using identifiable genetic and medical information.
F. Federal Law No. 86-FZ of 5 July 1996
On State Regulation in the Field of Genetic Engineering Activities
This law is relevant to research involving genetically engineered organisms and related technologies.
Its importance for research integrity includes:
Compliance with applicable safety requirements.
Responsible handling of genetically modified organisms.
Prevention of unlawful genetic-engineering activities.
Compliance with applicable licensing and regulatory procedures.
Protection of human health and the environment.
A laboratory cannot justify unsafe genetic-engineering practices merely by claiming that the research has scientific importance.
G. Civil Code of the Russian Federation
The Civil Code is relevant to the ownership, attribution and commercial exploitation of biotechnology research results.
Important provisions include:
Article 1228: Author of the result of intellectual activity.
Article 1259: Copyright protection of scientific works.
Article 1350: Patentability of inventions.
Article 1370: Service inventions.
Article 1395: Patent applications abroad in circumstances involving Russian inventions.
These provisions become important when research misconduct involves:
Plagiarism.
False claims of scientific authorship.
Unauthorised use of laboratory discoveries.
Misappropriation of genetic-engineering inventions.
Disputes over inventorship.
Commercial exploitation of another researcher's work.
A scientific discovery is not automatically protected as copyright merely because it is scientifically valuable. Copyright protection generally concerns the form in which a scientific work is expressed.
Library of Congress Tiles+1
3. Meaning and forms of biotechnology research misconduct
Russian research-integrity issues can be examined through several recognised categories of scientific misconduct.
A. Fabrication of research data
Fabrication occurs when a researcher invents experimental results that were never obtained.
Examples include:
Creating fictional genetic-sequencing results.
Inventing vaccine efficacy statistics.
Reporting experiments that never occurred.
Fabricating clinical-trial participants.
Creating false laboratory observations.
Such conduct may result in institutional disciplinary action, termination of research funding, civil liability or criminal proceedings if the elements of an applicable offence are established.
B. Falsification of research findings
Falsification involves manipulating genuine research data or experimental procedures to produce misleading conclusions.
Examples include:
Altering DNA-sequencing results.
Removing unfavourable experimental observations.
Manipulating images of laboratory experiments.
Concealing adverse reactions in clinical trials.
Changing statistical results without scientific justification.
In clinical research, falsification may also undermine the reliability of regulatory submissions.
C. Plagiarism and scientific authorship misconduct
Plagiarism occurs when a researcher presents another person's scientific work as their own without appropriate attribution.
In biotechnology, it may involve:
Copying genetic research findings.
Misappropriating laboratory protocols.
Publishing another researcher's experimental data.
Falsely claiming authorship of a scientific discovery.
The legal consequences depend on whether the conduct also violates copyright, employment obligations, research agreements or institutional rules.
D. Selective reporting of clinical-trial results
Selective reporting is particularly concerning in pharmaceutical and biotechnology research.
For example, a researcher may publish favourable vaccine efficacy results while concealing serious adverse events.
Such conduct can compromise:
Patient safety.
Scientific reproducibility.
Regulatory evaluation.
Public confidence in biological medicines.
The reliability of subsequent research.
E. Conflicts of interest
Research integrity also requires appropriate management of conflicts of interest.
For example, a pharmaceutical company funding a university's biotechnology research may have a financial interest in obtaining favourable results.
The existence of industry funding does not itself establish misconduct. However, undisclosed financial relationships, manipulated findings or biased reporting may undermine the integrity of the research.
4. Regulatory institutions and research-integrity supervision
Several institutions contribute to the Russian regulatory framework.
| Institution | Relevant responsibility |
|---|---|
| Ministry of Science and Higher Education | Scientific policy and research administration |
| Ministry of Health | Medical research and clinical-trial regulation |
| Ethics Council of the Ministry of Health | Ethical assessment in the statutory clinical-trial approval process |
| Roszdravnadzor | Supervision in the healthcare and medical-product regulatory sphere |
| Rospotrebnadzor | Public-health and sanitary oversight |
| Federal Service for Intellectual Property (Rospatent) | Patent and intellectual-property administration |
| Research institutions | Internal scientific and ethical supervision |
| Russian Academy of Sciences | Scientific assessment and activities addressing research falsification |
The Russian Academy of Sciences has also had a Commission for Counteracting the Falsification of Scientific Research.
Its activities are important in identifying questionable publications and scientific practices. However, it should not be confused with a criminal court or a general statutory enforcement regulator.
Important distinction regarding ethics committees: An institution's local ethics committee cannot automatically substitute for the legally required approval of a clinical trial by the competent federal authorities.
A 2021 study examining Russian medical publications identified substantial compliance problems involving unauthorised clinical investigations.
PMC+1
5. Important case laws concerning biotechnology research integrity in Russia
Russian judicial decisions specifically addressing fabrication or falsification of biotechnology research are limited. Nevertheless, decisions concerning clinical-trial safety, informed consent and medical-research accountability provide important legal principles.
Case 1. Traskunova v. Russia (2022)
Highly relevant case
Court: European Court of Human Rights, Third Section.
Application No.: 21648/11.
Judgment date: 30 August 2022.
Legal provision: Article 2, European Convention on Human Rights.
Facts of the case
The applicant's daughter suffered from schizophrenia and participated in clinical trials of asenapine, an experimental medicine intended to treat schizophrenia.
She died in April 2006 after developing serious medical complications during the trial.
The applicant alleged that the medical professionals had failed to conduct adequate medical examinations before enrolling her daughter and had not properly monitored her health during the clinical investigations.
Legal issues
The Court examined:
Whether the Russian authorities had effectively implemented the clinical-trial regulatory framework.
Whether the participant's health had been adequately monitored.
Whether the safeguards for vulnerable research participants had been respected.
Whether the domestic investigation provided an adequate judicial response.
Judgment
The European Court found a violation of Article 2, the right to life.
It concluded that Russia had failed to ensure the effective implementation and functioning of the legal framework protecting the participant's life during clinical trials.
The Court also emphasised the need for particularly strong safeguards when persons with mental illness participate in clinical research.
Importance for biotechnology research integrity
This judgment establishes several important principles:
Clinical-trial procedures must be implemented effectively, not merely exist on paper.
Researchers must properly assess participants before enrolment.
Continuous medical monitoring is essential.
Vulnerable participants require heightened protection.
Regulatory authorities must ensure that clinical-trial safeguards work in practice.
Investigations into serious research-related harm must be effective.
Legal principle: Scientific research cannot take priority over the protection of human life and the effective implementation of participant-safety safeguards.
This is an important authority for research involving gene therapies, experimental biological medicines and other innovative medical products.
BAILII+2
Case 2. Hristozov and Others v. Bulgaria (2012)
Court: European Court of Human Rights.
Applications: 47039/11 and 358/12.
Judgment date: 13 November 2012.
Legal provisions: Articles 2 and 8 of the European Convention.
Facts
The applicants were seriously ill cancer patients who wanted access to experimental medicinal products that had not received marketing authorisation.
They challenged the national restrictions preventing their access to the experimental treatments.
Decision
The Court examined the relationship between experimental treatment, regulatory authorisation and the rights protected under the Convention.
It did not establish an unrestricted right to receive experimental medicines.
Relevance to Russia
This is not a Russian case. It is a comparative European authority that helps explain why experimental biotechnology products require reliable evidence, regulatory assessment and transparent safety procedures.
It is useful when discussing the tension between scientific innovation and patient protection.
PubMed Central (PMC)+1
Case 3. Russian clinical-trial compliance controversy examined in the 2021 study
Unapproved Clinical Trials in Russia: Exception or Norm? (2021)
Publication: BMC Medical Ethics.
DOI: 10.1186/s12910-021-00617-3.
Authors included members of the Russian Academy of Sciences Commission for Counteracting the Falsification of Scientific Research.
Facts and findings
The researchers examined 26 publications reporting clinical trials conducted in Russia.
They found:
22 publications reported unauthorised clinical trials.
Three of those trials involved children.
Nine studies used medicines in ways that did not match approved labelling.
Fourteen publications or journal issues contained advertisements for the relevant medicine or its manufacturer.
Legal significance
The study identified problems involving:
Prior regulatory authorisation.
Independent scientific evaluation.
Ethical assessment.
Possible commercial conflicts of interest.
Reliability of published research results.
Important qualification: This is a scientific investigation, not a court judgment. It does not establish that every researcher or sponsor involved committed a legally proven offence.
Nevertheless, it is an important source for understanding the practical challenges of research integrity in Russia.
PMC+1
Case-law assessment
These authorities illustrate three different aspects of research integrity:
| Authority | Main principle |
|---|---|
| Traskunova v. Russia (2022) | Effective protection of clinical-trial participants |
| Hristozov and Others v. Bulgaria (2012) | Regulatory control of experimental medicines |
| 2021 Russian clinical-trial study | Scientific and ethical compliance in clinical research |
The first is the directly relevant Russian human-rights judgment. The second is comparative jurisprudence. The third is empirical research rather than judicial precedent.
6. Criminal and civil liability for research-integrity violations
Research misconduct does not automatically constitute a criminal offence in Russia. Liability depends on the particular conduct, applicable legal provisions and evidence.
A. Criminal liability
The Russian Criminal Code may become relevant in cases involving:
| Provision | Potential relevance |
|---|---|
| Article 159 | Fraud involving research funding or scientific contracts |
| Article 285 | Abuse of official powers by relevant officials |
| Article 293 | Negligence by persons falling within its statutory scope |
| Article 327 | Forgery of official documents in circumstances covered by the provision |
| Article 238 | Provision of goods or services that fail to meet applicable safety requirements, where the statutory elements are satisfied |
For example, deliberately submitting fabricated research documentation to obtain public funding could potentially raise fraud issues.
However, a false scientific conclusion alone does not automatically satisfy the elements of Article 159 or any other criminal offence.
B. Civil liability
Civil liability may arise where research misconduct causes legally recognised harm.
Examples include:
Injury to clinical-trial participants.
Financial losses resulting from fraudulent research contracts.
Unauthorised exploitation of protected intellectual property.
Breach of contractual research obligations.
Damage resulting from unlawful disclosure of personal or medical information.
The relevant provisions of the Civil Code include Articles 15 and 1064, concerning damages and general liability for causing harm.
C. Employment and institutional liability
Research institutions may impose disciplinary consequences where employees violate applicable employment obligations.
Possible consequences include:
Official warnings.
Disciplinary reprimands.
Dismissal where legally justified.
Withdrawal or correction of scientific publications.
Internal investigations.
Reporting to funding or regulatory authorities.
Review of academic qualifications under the applicable procedures.
A finding of plagiarism or scientific misconduct does not, by itself, automatically invalidate every patent or scientific qualification connected with the researcher.
7. International standards influencing Russian biotechnology research integrity
Russian biotechnology research also operates within a broader international scientific and ethical environment.
Important standards include:
A. Declaration of Helsinki
Establishes ethical principles for medical research involving human participants, including informed consent, independent ethical review and protection of vulnerable individuals.
B. International Council for Harmonisation – Good Clinical Practice (ICH-GCP)
Provides standards concerning clinical-trial design, documentation, investigator responsibilities, participant protection and research-data reliability.
C. UNESCO Universal Declaration on Bioethics and Human Rights (2005)
Addresses human dignity, autonomy, informed consent, privacy, equality and the ethical responsibilities associated with biological and medical research.
D. Convention on Human Rights and Biomedicine (Oviedo Convention)
Provides international principles concerning human dignity, consent and biomedical research. Russia has not signed or ratified this Convention.
BAILII+2
8. Major legal challenges in Russia
Several challenges remain relevant to biotechnology research integrity.
1. Absence of a comprehensive research-integrity statute
The legal framework is distributed across different laws and regulations. There is no single comprehensive federal statute establishing a uniform definition and investigation procedure for all forms of scientific misconduct.
2. Inconsistent institutional oversight
Research institutions may have internal ethics committees, but institutional review does not necessarily replace the approval required by federal clinical-trial legislation.
3. Scientific-data falsification
Manipulation of genomic results, laboratory observations and clinical-trial statistics can undermine the reliability of biotechnology research.
4. Conflicts of interest
Commercial sponsorship may create pressure to produce favourable results, particularly in pharmaceutical and vaccine development.
5. Weak reproducibility and transparency
Insufficient publication of experimental methods, negative results and underlying data makes independent verification difficult.
6. Genetic-data protection
Research involving DNA sequencing and genomic databases creates additional privacy and confidentiality concerns.
7. International research collaboration
Differences in ethical-review requirements, data-protection obligations and scientific standards may complicate cross-border biotechnology projects.
9. Recommendations for strengthening research integrity
Russian biotechnology institutions can strengthen compliance through the following measures:
Establish independent research-integrity committees.
Introduce standard procedures for investigating fabrication and falsification.
Require complete and traceable laboratory records.
Maintain secure records of genomic and clinical-trial data.
Require disclosure of financial conflicts of interest.
Strengthen independent clinical-trial monitoring.
Protect whistleblowers reporting scientific misconduct.
Introduce transparent authorship and publication policies.
Require appropriate ethical approval before human-subject research.
Establish clear procedures for correcting or retracting unreliable scientific publications.
10. Conclusion
Biotechnology Research Integrity Law in Russia is based on a combination of scientific legislation, pharmaceutical regulation, healthcare law, personal-data protection, intellectual-property law and general civil and criminal liability.
Federal Law No. 127-FZ establishes important responsibilities for scientific workers. Federal Law No. 61-FZ regulates pharmaceutical clinical trials, while Federal Law No. 323-FZ protects patients and research participants. Federal Law No. 152-FZ provides additional safeguards for sensitive personal and medical information.
The judgment in Traskunova v. Russia (2022) is particularly significant because it demonstrates that the existence of clinical-trial regulations is insufficient unless authorities ensure their effective implementation.
Ultimately, biotechnology research integrity requires three fundamental safeguards:
Scientific integrity: Accurate, reproducible and transparent research.
Ethical integrity: Respect for human dignity, informed consent and participant safety.
Legal accountability: Effective institutional, civil, administrative and criminal mechanisms where applicable.
Russia's regulatory framework provides important protections, but the absence of a unified research-integrity statute and the practical difficulties identified in clinical-trial research remain significant legal and institutional challenges.
11. Important legislation and references for academic research
| Legal authority | Subject |
|---|---|
| Constitution of Russia | Fundamental rights and scientific freedom |
| Federal Law No. 127-FZ (1996) | Science and scientific policy |
| Federal Law No. 86-FZ (1996) | Genetic engineering |
| Federal Law No. 152-FZ (2006) | Personal-data protection |
| Federal Law No. 61-FZ (2010) | Medicines and clinical trials |
| Federal Law No. 323-FZ (2011) | Healthcare and patient rights |
| Civil Code of Russia | Intellectual property and civil liability |
| Criminal Code of Russia | Applicable criminal offences |
| Ministry of Health Order No. 200n (2016) | Good Clinical Practice |
Recommended academic and judicial sources
Traskunova v. Russia, Application No. 21648/11, ECtHR, 30 August 2022.
Talantov et al., Unapproved Clinical Trials in Russia: Exception or Norm?, BMC Medical Ethics (2021).
Federal Law No. 127-FZ, On Science and State Scientific and Technical Policy.
Federal Law No. 61-FZ, On Circulation of Medicines.
Library of Congress, Bioethics Legislation in Selected Countries: Russia.
Useful original references:
Read Traskunova v. Russia (2022)
Read the 2021 clinical-trial integrity study
Final academic observation: For legal research, it is important to distinguish proven judicial findings from allegations of scientific misconduct, institutional investigations and academic criticism. The available authorities provide substantial guidance on clinical-trial integrity, but they should not be misrepresented as establishing a comprehensive Russian judicial doctrine on biotechnology research fabrication and falsification.

comments